07/31/2025 8:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
07/18/2025 4:23 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
07/18/2025 4:23 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
07/18/2025 4:23 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
06/27/2025 4:15 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
06/27/2025 4:16 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
06/27/2025 4:16 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
06/13/2025 3:19 PM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/04/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
06/02/2025 4:23 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
06/02/2025 4:24 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
Get the Latest News and Ratings for BDRX and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Biodexa Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.
|
05/30/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/28/2025 4:59 PM | Biodexa Pharmaceuticals (Subject) C/M CAPITAL PARTNERS, LP (Filed by)
| Form SCHEDULE 13G | |
05/22/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/15/2025 4:16 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
05/15/2025 4:16 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
05/12/2025 7:31 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
05/11/2025 11:15 PM | Biodexa Pharmaceuticals (Filer)
| Form EFFECT | |
05/11/2025 11:15 PM | Biodexa Pharmaceuticals (Filer)
| Form EFFECT | |
05/11/2025 11:15 PM | Biodexa Pharmaceuticals (Filer)
| Form EFFECT | |
05/12/2025 5:02 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
05/12/2025 5:02 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
05/12/2025 5:02 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
04/29/2025 3:15 PM | Biodexa Pharmaceuticals (Filer)
| Form POS AM | |
04/17/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/11/2025 7:41 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
04/11/2025 7:43 AM | Biodexa Pharmaceuticals (Filer)
| Form 20-F Registration statement / Annual report / Transition report | |
03/10/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/10/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
03/06/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/24/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/18/2025 3:30 PM | Biodexa Pharmaceuticals (Subject) C/M CAPITAL PARTNERS, LP (Filed by)
| Form SCHEDULE 13G | |
02/13/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
02/10/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/27/2025 11:15 PM | Biodexa Pharmaceuticals (Filer)
| Form EFFECT | |
01/28/2025 5:00 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/22/2025 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/21/2025 5:27 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/21/2025 5:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/21/2025 5:18 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/21/2025 5:21 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
Get This Stock Now (Ad) This company is the lifeblood of AI data centers, yet almost no one has caught up with the story. Their hardware is so essential that the data center industry uses enough of it to stretch around the world 8 times – in a single building! So, if you own Nvidia stock now, you might be well-served to sell those shares and check out this under-the-radar play instead. Or if you missed the boat on Nvidia, this is a rare second chance to target tremendous profit potential as AI data centers spring up in every corner of the world. Get my full take on this exciting play right here… |
01/21/2025 5:24 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/21/2025 5:12 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/21/2025 5:15 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/17/2025 3:49 PM | Biodexa Pharmaceuticals (Filer)
| Form F-1 Registration statement for securities of certain foreign private issuers | |
01/17/2025 3:21 PM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
01/08/2025 5:00 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/08/2025 5:03 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/08/2025 5:06 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/08/2025 5:09 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/08/2025 5:12 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/08/2025 5:15 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
01/08/2025 5:18 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
12/27/2024 4:15 PM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
11/20/2024 10:56 AM | Biodexa Pharmaceuticals (Subject) Brio Capital Master Fund Ltd. (Filed by)
| Form SC 13G/A | |
11/05/2024 5:09 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
11/05/2024 5:12 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
11/05/2024 5:15 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
11/05/2024 5:06 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
11/05/2024 5:06 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
11/05/2024 5:00 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
11/05/2024 5:03 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
11/01/2024 4:18 PM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/16/2024 8:12 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
10/16/2024 8:12 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
10/16/2024 8:12 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
10/16/2024 8:12 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
10/16/2024 8:12 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
10/16/2024 8:12 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
10/16/2024 8:12 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
10/15/2024 4:14 PM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
10/04/2024 7:30 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/27/2024 3:41 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/27/2024 3:41 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/27/2024 3:41 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/27/2024 3:41 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/27/2024 3:41 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/27/2024 3:41 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/27/2024 3:41 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/26/2024 7:42 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/20/2024 3:36 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/20/2024 3:36 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/20/2024 3:36 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/20/2024 3:36 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/20/2024 3:36 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/20/2024 3:36 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/20/2024 3:36 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/19/2024 3:30 PM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/16/2024 7:40 AM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
09/06/2024 6:54 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/06/2024 6:54 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
Is Elon's empire crumbling? (Ad) The Tesla Shock Nobody Sees Coming
While headlines scream "Tesla is doomed"...
Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs.
One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as October 23rd. Click here to see the Tesla shock that could blindside everyone. |
09/06/2024 6:54 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/06/2024 6:54 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/06/2024 6:54 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/06/2024 6:54 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
09/06/2024 6:54 PM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |
08/30/2024 3:38 PM | Biodexa Pharmaceuticals (Filer)
| Form 6-K Report of foreign private issuer pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934 | |
08/19/2024 11:15 PM | Biodexa Pharmaceuticals (Filer)
| Form EFFECT | |
08/20/2024 5:00 AM | Biodexa Pharmaceuticals (Filer)
| Form 424B3 | |